Our results further demonstrate alterations in the activity of numerous other signalling pathways in neuroblastoma cells after treatment with regorafenib, including the PI3K/mTOR/Akt and Fos/Jun pathways. This evidence concerns the gene AKT1 and neuroblastoma.